Psoriatic Disease: Current Therapeutic Recommendations and Cost Management Considerations in Specialty Pharmacy


Robin Dore, MD
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA

Click here for biography

James Kenney, Jr., RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care

Click here for biography

Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center

Click here for biography



Psoriasis and psoriatic arthritis presents a significant clinical and humanistic burden to patients. Patients diagnosed with psoriatic disease are subject to increased mortality rates and functional disability which may lead to significant impairment in quality of life and increased use of health care resources. Fortunately, there has been a marked increase in the number of safe and effective therapies to the disease. The pathologic complexity of psoriatic disease and the comorbidities frequently requires collaborative multidisciplinary care. Improved awareness of therapeutic options available to manage the spectrum of pathologic challenges confronted by patients with psoriatic disease will enable HCDMs and specialty pharmacy providers to improve patient quality of life and clinical outcomes.

After completing this activity, the participant should be better able to:

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Name of Faculty or Presenter Reported Financial Relationship
Robin Dore, MD

Contracted Research: Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Lilly USA, LLC, and Novartis Pharmaceuticals Corporation

Consulting Fees (eg, Advisory Boards): Amgen, Inc., AbbVie, Inc., Lilly USA, LLC, and Novartis Pharmaceuticals Corporation

Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., Speakers’ Bureau): Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Celgene Corporation, and Novartis Pharmaceuticals Corporation

James Kenney, Jr., RPh, MBA The faculty member has nothing to disclose.
Alan Menter, MD

Advisory Board for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Boehringer Ingleheim Pharmaceuticals, Inc., Eli-Lilly, Janssen Biotech, Inc., LEO Pharma

Consulting fees from AbbVie, Inc., Allergan Pharmaceuticals, Amgen Inc., Eli-Lilly, Galderma, Janssen Biotech, Inc., LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer,Inc., Vitae, Xenoport

Investigator for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Anacor, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Dermira, Eli-Lilly, Janssen Biotech, Inc., LEO Pharma, Merck, Neothetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Symbio / Maruho, Xenoport

Speakers’ Bureau for AbbVie, Inc., Amgen, Janssen Biotech, Inc., Leo Pharma

The PIM planners and managers have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period of June 30, 2018, through December 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CPE activity, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.


There is no fee for this educational activity.